Buscar
Akebia Therapeutics Inc
AKBAAñadir a la lista de seguimiento
1.220USD
0.0000.00%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
326.84MCap. mercado
PérdidaP/E TTM
Más Datos de Akebia Therapeutics Inc Compañía
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Información de Akebia Therapeutics Inc
Símbolo de cotizaciónAKBA
Nombre de la empresaAkebia Therapeutics Inc
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoButler (John P)
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 20
Dirección245 First Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16178712098
Sitio Webhttps://akebia.com/
Símbolo de cotizaciónAKBA
Fecha de salida a bolsaMar 20, 2014
Director ejecutivoButler (John P)
Ejecutivos de Akebia Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+29.06%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
49.35K
-113.52%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Akebia Therapeutics Inc?
Los cinco principales accionistas de Akebia Therapeutics Inc son: Mr. John P. Butler
¿Cuántas instituciones poseen acciones de Akebia Therapeutics Inc (AKBA)?
A fecha de 2026Q1, 351 instituciones poseen acciones de Akebia Therapeutics Inc, con un valor de mercado combinado de aproximadamente 125.97M, lo que representa el 46.96% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -14935721.00.